Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC)

Enzalutamide, a nonsteroidal second-generation antiandrogen, has been recently approved for the management of castration-resistant prostate cancer (CRPC). Although patients can benefit from enzalutamide at the beginning of this therapy, acquired enzalutamide resistance usually occurs within a short...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Biol Chem
Asıl Yazarlar: Kong, Yifan, Cheng, Lijun, Mao, Fengyi, Zhang, Zhuangzhuang, Zhang, Yanquan, Farah, Elia, Bosler, Jacob, Bai, Yunfeng, Ahmad, Nihal, Kuang, Shihuan, Li, Lang, Liu, Xiaoqi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Biochemistry and Molecular Biology 2018
Konular:
Cell Biology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6139550/
https://ncbi.nlm.nih.gov/pubmed/30089652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1074/jbc.RA118.004442
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller